24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial

Breast Cancer

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

Ann Oncol

Mayer EL, Bidard FC, Park YH, Janni W, Ma C, Cristofanilli M, Iwata H, Bianchini G, Kalinsky K, Chia S, Brufsky A, Fasching PA, Nowecki Z, Chen SC, Pascual J, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Sohn JH, Zhu Y, Leddin I, Miralles MS, Bartlett CH, Turner N

doi: 10.1016/j.annonc.2025.10.006

Breast Cancer

Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial

Int J Cancer

Hörner M, Schäffler H, Häberle L, Goossens C, Pfister K, Leinert E, Veselinovic K, Brucker SY, Köhler U, Heinrich G, Schneeweiss A, Beckmann MW, Fasching PA, Janni W, Rack B, Heublein S, Ziegler P

doi: 10.1002/ijc.70528

Breast Cancer

CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials

Lancet Oncol

Beshr MS, Fahaid A, Shembesh RH, Valachis A, Lambertini M, Cortesi L, Alesawy AF, Abraheem A, Alsharedi M, Ali ME, Elkhanany A, Azim HA Jr, Velikova G, Elhadi M

doi: 10.1016/S1470-2045(26)00053-7

Breast Cancer

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

JAMA Oncol

Fasching PA, Stroyakovskiy D, Yardley DA, Huang CS, Crown J, Bardia A, Chia S, Im SA, Martin M, Xu B, Loi S, Barrios C, Untch M, Moroose R, Visco F, Hortobagyi GN, Slamon DJ, Fresco R, Zarate JP, Li Z, Waters S, Hurvitz SA

doi: 10.1001/jamaoncol.2025.3700

Breast Cancer

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

Ann Oncol

Burstein HJ, Curigliano G, Gnant M, Loibl S, Regan MM, Loi S, Denkert C, Poortmans P, Cameron D, Thurlimann B, Weber WP, Panelists of the St. Gallen International Breast Cancer Consensus 2025

doi: 10.1016/j.annonc.2025.09.007

ESMO 2025

Breast Cancer

NATALEE: Ribociclib plus adjuvant endocrine therapy sustains iDFS benefit two years post-treatment in patients with HR+/HER2− breast cancer

Breast Cancer

Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database

Eur J Cancer

Aristei C, Tomatis M, Ponti A, Marotti L, Battisti NML, Leung Cheung K, Hartmann OJ, Rubio IT, Santini D, Sardanelli F, Senkus E, van Dam P, Curigliano G, Eusoma Working Group

doi: 10.1016/j.ejca.2026.116259

RECOMMENDED

Breast Cancer

Compression therapy with surgical gloves compared to cold therapy with frozen gloves in preventing paclitaxel-induced peripheral neuropathy: Results from the prospective ELEGANT trial in patients with breast cancer

★ 1 Recommended by Dr Andreas Müller, Faculty Member

★ 2 Recommended by Prof. Dr Beat Thürlimann, Faculty Member

Eur J Cancer

Hanvic B, Joureau-Chabert A, Ouldbey Y, Toussaint P, Chanel E, Blanc E, Heudel P, Montagnier V, Pérol D, Bachelot T

doi: 10.1016/j.ejca.2025.115791

Breast CancerGynecologic Cancer

The Experience of Women With Breast or Gynecological Cancer After Participation in an Online Mindfulness-Based Cancer Recovery (e-MBCR) Program: Secondary Outcomes Analysis of a Pilot Mixed Methods Randomized Controlled Trial

Psychooncology

Gaignard ME, Martin D, Stanic J, Hilfiker R, Bodmer A, Ljuslin M, Zaman K, Labidi-Galy I, Sarivalasis A, Carlson LE, Peters S, Dietrich PY, Eicher M, Bondolfi G, Jermann F

doi: 10.1002/pon.70334

Related content

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

Chemotherapy-Induced Nausea and Vomiting in Early Breast Cancer Patients Receiving Adjuvant Chemotherapy With Fluorouracil, Epirubicin, Cyclophosphamide Followed by Docetaxel Versus an Anthracycline-Free Regimen With Docetaxel, Cyclophosphamide-Results From a Randomized Clinical Trial

CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials

Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial

Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer

NATALEE: Ribociclib plus adjuvant endocrine therapy sustains iDFS benefit two years post-treatment in patients with HR+/HER2− breast cancer

Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database

Compression therapy with surgical gloves compared to cold therapy with frozen gloves in preventing paclitaxel-induced peripheral neuropathy: Results from the prospective ELEGANT trial in patients with breast cancer

The Experience of Women With Breast or Gynecological Cancer After Participation in an Online Mindfulness-Based Cancer Recovery (e-MBCR) Program: Secondary Outcomes Analysis of a Pilot Mixed Methods Randomized Controlled Trial